Neuromyelitis Optica Disorders: A Retrospective Observational Study: Experience of Tertiary Hospital in Central India
Abstract
Keywords
Full Text:
PDFReferences
Papp V, Illes Z, Magyari M, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology. 2018; 91(24): E2265–E2275. doi:10.1212/WNL.000000 0000006645
Jonsson DI, Sveinsson O, Hakim R, et al. Epidemiology of NMOSD in Sweden from 1987 to 2013: a nationwide population-based study. Neurology. 2019; 93(2): E181–E189. doi:10.1212/WNL.000000000 00077463.
Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177–89.
Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805–815.
Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009; 256(11): 1891–1898.
Mealy M, Wingerchuck D, Greenberg B, et al. Epidemiology of neuromyelitis optica in the United States, a multicenter analysis. Arch Neurol. 2012; 69(9): 1176–1180.
Pandit L, Mustafa S. Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Ann Indian Acad Neurol. 2013; 16(4): 572–576.
Siritho S, Nakashima I, Takahashi T, et al. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. Neurology. 2011; 77(9): 827–834.
Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011; 76(18): 1589–1595.
Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. J Neurol Sci. 2009; 286(1–2): 58–61.
Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology. 2010; 74(9): 736–742.
Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012; 9: 14.
Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler. 2013; 20(8): 1086– 1094.
Kitley J, Leite MI, Küker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol. 2013; 70(11): 1375–1381.
Collongues N, Marignier R, Zephir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology. 2010; 75(12): 1084–1088.
Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler J. 2015; 21(7): 845–853. DOI: 10.1177/ 1352458515572406.
Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Exp Ophthalmol. 2001; 29(5): 312–315. [PubMed] [Google Scholar] [Ref list]
Kim HJ, Park KA. Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. Korean J Ophthalmol. 2019; 33(1): 82–90. https://doi.org/10.3341/kjo.2018.0050.
Joshi PB, Shah SD, et al. A Study of Neuromyelitis Optica Spectrum Disorders (NMOSD): Disease Pattern Based on Antibody Status. Neurol India. 2022; 70(3): 1131–6.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63(3): 390–6.
Marignier R, Bernard‐Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, et al. Aquaporin‐4 antibody‐negative neuromyelitis optica: Distinct assay sensitivity‐dependent entity. Neurology. 2013; 80(24): 2194–2200.
Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, et al. Neuromyelitisoptica spectrum disorders with aquaporin-4 and myelin-oligodendrocyteglyco-protein antibodies: a comparative study. JAMA Neurol. 2014; 71(3): 276–283.
Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol. 2012; 44(9): 1519–1530.
Sherman E, Han MH. Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder. Curr Treat Options Neurol. 2015; 17(11): 48.
Takai Y, Misu T, Nakashima I, et al. Two cases of lumbosacral myeloradiculitis with anti- aquaporin-4 antibody. Neurology. 2012; 79(17): 1826–1828.
BukhariW, Clarke L. The clinical profile of NMOSD in Australia and New Zealand. J Neurol. 2020 May; 267(5): 1431–1443. doi: 10.1007/s00415-020-09716-4. Epub 2020 Jan 31.
Khedr, et al. Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns. Egypt J Neurol Psychiatry Neurosurg. 2021; 57: 155.
Salama S, Marouf H, et al. Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. J Neuroimmunol. 2018; 324: 22–25. https:// doi. org/ 10. 1016/j. jneur oim. 2018. 08. 014.
Fan R, Zhang Y, et al. Serum antinuclear antibodies associate with worse prognosis in AQP4- positive neuromyelitis optica spectrum disorder Brain Behav. 2021; 11(1): e01865. 1–8 https://doi.org/10.1002/brb3.1865.
Fukuda TG, Silva TF, et al. Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil. BMC Neurol. 2022; 22(1): 95. https://doi.org/10.1186/s12883-022-02621-5
Wu J-S, Zhang M-N, et al. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatr. 2008; 79(9): 1022–1026. doi: 10.1136/jnnp.2007.131177. [PubMed] [CrossRef] [Google Scholar] [Ref list]
Otto Jesus Hernandez Fustes, Cláudia SK, et al. Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. J Cent Nerv Syst Dis. 2021 Dec; 13: 11795735211057315(5p).
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Research & Reviews: A Journal of Health Professions
This Journal archive has been shifted to: https://journals.stmjournals.com/archive/rrjohp/